Category: infectious disease

Xavier Argemi first heard the claim that tea made from artemisia herbs could be useful in the treatment of malaria from a TV documentary in 2017.

The documentary, featuring Lucile Cornet-Vernet, the director of the La Maison de l’Artemisia, a non-profit organization that grows artemisia and promotes its use in centers across Africa, focused on the Democratic Republic of the Congo (DRC). The film claimed that for decades major pharmaceutical companies have been profiting from expensive malaria drugs based on artemisinin — the antimalarial for which Tu Youyou won a Nobel Prize in 2015, after distilling it from the Artemisia annua plant — while the tea itself, an ancient Chinese herbal remedy, was just as effective at treating the disease.

His interest piqued, Argemi reached out to Cornet-Vernet, an orthodontist at Paris’ Descartes University. She shared with him the unpublished manuscript of a study — their first large-scale clinical trial — which she said showed that artemisia outperformed a go-to treatment for schistosomiasis, a different parasite-induced disease.

Argemi immediately saw red flags. “I am not a specialist of malaria or schistosomiasis, but when I read the study I was simply totally surprised by the number of inconsistencies at the very first read,” Argemi, of the Clinique Axium in Strasbourg, France, told Retraction Watch by email. 

Continue reading A bitter aftertaste: Legal threats, alleged poisoning muddy the waters for a trial of a tea to treat malaria

An infectious diseases researcher found by a federal U.S. watchdog to have “recklessly” faked data in grants worth millions left his job as the investigation was coming to a close, Retraction Watch has learned.

As we reported last week, Prasadarao Nemani, of Children’s Hospital Los Angeles (CHLA) and the University of Southern California (USC), “engaged in research misconduct by recklessly including falsified and/or fabricated data” in a 2009 paper — retracted in 2018 — and four NIH grant applications, according to the U.S. Office of Research Integrity.

Earlier this week, in a statement provided to Retraction Watch, CHLA said that he was no longer with the hospital or with USC:

Continue reading USC-Children’s Hospital Los Angeles researcher out following misconduct probe

We have heard back this morning from the publisher of a journal that yanked a paper that linked 5G cellphone technology and the novel coronavirus last week — a paper that scientific sleuth Elisabeth Bik mused was the “worst paper of 2020.”

The response to our request for comment from editor in chief Pio Conti reads a bit like a Mad Libs of excuses we hear from publishers when something goes wrong. Read carefully for:

Continue reading ‘Some papers can slip through the net,’ says journal that published 5G-COVID-19 paper

A public health journal will be retracting a paper that argued for the adoption of homeopathy in the fight against the coronavirus pandemic, according to the editor in chief.

We reported on Saturday that the Journal of Public Health: From Theory to Practice, a Springer Nature title also known by its German name, Zeitschrift für Gesundheitswissenschaften, had published “Homeopathy combat against coronavirus disease (Covid-19)” on June 5.

At the time, we had not yet heard from Joachim Kugler, the journal’s editor, about how this might have happened. Today, Kugler told Retraction Watch:

Continue reading Blaming “overflow of manuscripts” and “obviously biased” reviewers, journal will retract homeopathy-COVID-19 paper

A paper which argued that 5G cellphone technology could lead to infection with the novel coronavirus has been retracted, but not before scientific sleuth Elisabeth Bik wondered whether it was the “worst paper of 2020.”

The article, “5G Technology and induction of coronavirus in skin cells,” came from a group from Italy, the United States and Russia, and appeared in the Journal of Biological Regulators and Homeostatic Agents. The journal is published by Biolife, which asserts that it’s peer reviewed but has not responded to a request for comment. [Please see an update on this post.]

The abstract is now marked “WITHDRAWN” on PubMed and the paper has disappeared from the journal’s website. The abstract has been preserved here. According to the authors: 

Continue reading Paper blaming COVID-19 on 5G technology withdrawn

A peer-reviewed journal has published a paper that urges the adoption of homeopathy in the fight against the coronavirus pandemic.

[Please see an update on this post.]

The Journal of Public Health: From Theory to Practice — published by Springer Nature and also known by its German name, Zeitschrift für Gesundheitswissenschaften — published “Homeopathy combat against coronavirus disease (Covid-19)” on June 5. It is indexed in PubMed Central, although not on Medline.

Here’s the abstract:

Continue reading Paper urging use of homeopathy for COVID-19 appears in peer-reviewed public health journal

Didier Raoult, whose claims that hydroxychloroquine can treat COVID-19 have been widely disputed, has had a 2018 paper corrected for what his team says was unintentional duplication of a figure.

Here’s the correction for “Identification of rickettsial immunoreactive proteins using a proximity ligation assay Western blotting and the traditional immunoproteomic approach,” which came four months after scientific sleuth Elisabeth Bik pointed out potential issues in Figure 2 on PubPeer:

Continue reading Co-author of controversial hydroxychloroquine study has 2018 paper corrected for “unintentional mistake”

Yesterday, dozens of scientists petitioned the Proceedings of the National Academy of Sciences to “retract a paper on the effectiveness of masks, saying the study has ‘egregious errors’ and contains numerous ‘verifiably false’ statements,” as The New York Times reported. One of those scientists was James Heathers, whose name will likely be familiar to Retraction Watch readers because of his work as a scientific sleuth. We asked him to share his thoughts on why he signed the letter.

Recently, The Lancet retracted a paper critical of the drug hydroxychloroquine in the treatment of COVID. The retraction was requested by three of the paper’s authors, who had requested a copy of the underlying data from the fourth. The data never came. No data, no paper.

The above took a few weeks. To many people, it must have looked like silence. But the entire time, out of the public eye, a furious and detailed global discussion between scientists, statisticians, and epidemiologists about the accuracy of this paper was boiling. Frankly, almost no one believed this paper. The data were too regular. The access that was reported to hospital databases was too unusual. The amount of work done didn’t fit the parameters reported.

It was … “off.” It was obvious. Something was amiss.

Continue reading I agree with your conclusions completely, and your paper is still terrible.

A Springer Nature journal has issued an editor’s note — which seems an awful lot like an Expression of Concern — for a widely circulated but quickly contested paper about how the novel coronavirus might infect white blood cells, akin to HIV.

However, readers could be forgiven for missing that fact. Indeed, the journal itself appears to be struggling to deal with the article — which one of the corresponding authors told us he asked to withdraw weeks ago.

The paper, “SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion,” appeared in early April in Cellular & Molecular Immunology. Most of the authors are based in China, and one, Shibo Jiang, is a prominent virologist with a joint affiliation at the New York Blood Center.

Continue reading A journal took three days to accept a COVID-19 paper. It’s taken two months and counting to retract it.

On the heels of retractions of papers based on data that has fallen under intense scrutiny, an emergency medicine group in Africa is withdrawing a tool that they built using data from the same company.

Lee Wallis, one of the editors in chief of the African Journal of Emergency Medicine, described the tool, built in a partnership with the African Federation for Emergency Medicine (AFEM) and Surgisphere, in an April 2, 2020 editorial. A PubPeer commenter noted the potential issues today (June 6), and Wallis responded there nearly immediately to say that the tool was withdrawn.

In a statement, AFEM writes:

Continue reading Group withdraws COVID-19 scoring tool based on Surgisphere data following NEJM, Lancet retractions